Medpace (NASDAQ:MEDP) CEO August Troendle Sells 673 Shares of Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 673 shares of the business’s stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $620.38, for a total value of $417,515.74. Following the transaction, the chief executive officer owned 544,544 shares in the company, valued at approximately $337,824,206.72. This trade represents a 0.12% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Medpace Stock Performance

NASDAQ:MEDP traded down $7.48 during mid-day trading on Thursday, hitting $611.57. 198,148 shares of the company’s stock traded hands, compared to its average volume of 344,156. The company has a fifty day moving average of $559.49 and a 200 day moving average of $493.31. Medpace Holdings, Inc. has a twelve month low of $373.00 and a twelve month high of $677.90. The company has a market capitalization of $17.07 billion, a P/E ratio of 35.85, a P/E/G ratio of 2.74 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, topping the consensus estimate of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The business had revenue of $707.33 million during the quarter, compared to the consensus estimate of $689.51 million. During the same quarter last year, the company earned $3.10 earnings per share. The company’s quarterly revenue was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, research analysts expect that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have weighed in on MEDP shares. Truist Financial boosted their target price on shares of Medpace from $462.00 to $609.00 and gave the stock a “hold” rating in a research report on Friday, July 24th. Leerink Partners set a $620.00 price target on shares of Medpace in a report on Thursday, July 23rd. Mizuho lifted their price objective on shares of Medpace from $586.00 to $665.00 and gave the stock an “outperform” rating in a research note on Friday, July 24th. Weiss Ratings raised shares of Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, August 12th. Finally, Robert W. Baird raised their target price on Medpace from $547.00 to $624.00 and gave the stock a “neutral” rating in a research note on Friday, July 24th. Three investment analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $584.18.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the business. California State Teachers Retirement System increased its position in shares of Medpace by 22.1% during the first quarter. California State Teachers Retirement System now owns 26,042 shares of the company’s stock worth $12,505,000 after acquiring an additional 4,719 shares during the period. American Capital Management Inc. purchased a new stake in shares of Medpace in the second quarter valued at about $111,329,000. Focus Partners Advisor Solutions LLC acquired a new stake in shares of Medpace during the second quarter worth about $1,685,000. BlackRock Inc. purchased a new position in shares of Medpace during the second quarter worth about $1,323,047,000. Finally, Cerity Partners LLC increased its position in Medpace by 41.0% in the 4th quarter. Cerity Partners LLC now owns 80,973 shares of the company’s stock valued at $45,478,000 after acquiring an additional 23,530 shares during the period. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.